Ferràn Torres

19.9k total citations · 5 hit papers
248 papers, 11.1k citations indexed

About

Ferràn Torres is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Ferràn Torres has authored 248 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Epidemiology, 43 papers in Pulmonary and Respiratory Medicine and 40 papers in Hepatology. Recurrent topics in Ferràn Torres's work include Liver Disease Diagnosis and Treatment (33 papers), Liver Disease and Transplantation (21 papers) and Pulmonary Hypertension Research and Treatments (19 papers). Ferràn Torres is often cited by papers focused on Liver Disease Diagnosis and Treatment (33 papers), Liver Disease and Transplantation (21 papers) and Pulmonary Hypertension Research and Treatments (19 papers). Ferràn Torres collaborates with scholars based in Spain, United States and Italy. Ferràn Torres's co-authors include Anna M. Planas, José Ríos, Álvaro Cervera, Nazzareno Galiè, Vı́ctor Obach, Adaani Frost, Hossein Ardeschir Ghofrani, Martha Vargas, Ángel Chamorro and Lewis J. Rubin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Circulation.

In The Last Decade

Ferràn Torres

235 papers receiving 10.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

2008 785 citations Nazzareno Galiè, Horst Olschewski et al. Circulation profile →
High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients

2013 480 citations Ferràn Torres et al. profile →
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension

2013 411 citations Marius M. Hoeper, Robyn J. Barst et al. Circulation profile →
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

2019 392 citations Càndid Villanueva, Agustı́n Albillos et al. profile →
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis

2022 94 citations Càndid Villanueva, Ferràn Torres et al. Journal of Hepatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ferràn Torres	3.0k	2.8k	2.1k	2.0k	1.7k	248	11.1k
Jackie Bosch	3.4k 1.1×	4.7k 1.7×	3.3k 1.6×	4.8k 2.4×	4.3k 2.5×	365	19.0k
Qilong Yi	1.5k 0.5×	2.2k 0.8×	1.2k 0.6×	1.2k 0.6×	3.1k 1.8×	204	10.7k
Uwe Heemann	1.5k 0.5×	1.1k 0.4×	643 0.3×	2.8k 1.4×	1.1k 0.7×	388	9.5k
Murray Epstein	2.6k 0.9×	1.9k 0.7×	2.2k 1.0×	2.4k 1.2×	5.0k 2.9×	261	13.3k
Allan Tsung	2.5k 0.8×	3.2k 1.1×	3.4k 1.6×	4.5k 2.3×	506 0.3×	342	18.1k
David A. Roth	2.9k 1.0×	2.0k 0.7×	1.2k 0.6×	3.0k 1.5×	4.1k 2.4×	212	20.6k
Christian Combe	1.0k 0.4×	1.2k 0.4×	630 0.3×	1.4k 0.7×	880 0.5×	338	10.3k
Z. Jennie	1.0k 0.4×	2.3k 0.8×	506 0.2×	1.6k 0.8×	1.3k 0.8×	190	11.1k
Steven J. Chadban	1.6k 0.5×	1.3k 0.5×	418 0.2×	2.7k 1.3×	1.0k 0.6×	283	12.8k
Gilles Châtellier	1.9k 0.6×	1.7k 0.6×	390 0.2×	4.1k 2.1×	5.3k 3.1×	414	13.8k

Countries citing papers authored by Ferràn Torres

Since Specialization

Citations

This map shows the geographic impact of Ferràn Torres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferràn Torres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferràn Torres more than expected).

Fields of papers citing papers by Ferràn Torres

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferràn Torres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferràn Torres. The network helps show where Ferràn Torres may publish in the future.

Co-authorship network of co-authors of Ferràn Torres

This figure shows the co-authorship network connecting the top 25 collaborators of Ferràn Torres. A scholar is included among the top collaborators of Ferràn Torres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferràn Torres. Ferràn Torres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sanduzzi‐Zamparelli, Marco, Andrés Castaño‐García, Neus Llarch, et al.. (2025). Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes. European Journal of Cancer. 221. 115404–115404.

Beaber, Brandon, et al.. (2025). Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 106(2). e214473–e214473.

Ouchi, Dan, et al.. (2023). Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia. Diabetes Research and Clinical Practice. 202. 110777–110777. 2 indexed citations

Ouchi, Dan, et al.. (2023). Impact of Second-Line Combination Treatment for Type 2 Diabetes Mellitus on Disease Control: A Population-Based Cohort Study. Drugs - Real World Outcomes. 10(3). 447–457. 1 indexed citations

Rowe, Ian, Càndid Villanueva, Ferràn Torres, et al.. (2023). Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial. Hepatology. 78(2). 530–539. 7 indexed citations

Carol, Marta, Martina Pérez, Elsa Solà, et al.. (2022). Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS ONE. 17(4). e0265153–e0265153. 23 indexed citations

Ouchi, Dan, et al.. (2022). Automatic Estimation of the Most Likely Drug Combination in Electronic Health Records Using the Smooth Algorithm: Development and Validation Study. JMIR Medical Informatics. 10(11). e37976–e37976. 3 indexed citations

Villanueva, Càndid, Ferràn Torres, Shiv Kumar Sarin, et al.. (2022). Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of Hepatology. 77(4). 1014–1025. 94 indexed citations breakdown →

Villanueva, Càndid, Agustı́n Albillos, Joan Genescà, et al.. (2021). Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology. 75(3). 589–599. 39 indexed citations

10.

Mandorfer, Mattias, Fanny Turón, Sabela Lens, et al.. (2021). Risk of non‐tumoural portal vein thrombosis in patients with HCV‐induced cirrhosis after sustained virological response. Liver International. 41(12). 2954–2964. 5 indexed citations

11.

Rodríguez‐Tajes, Sergio, Sabela Lens, Zoe Mariñó, et al.. (2020). Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. Journal of Hepatology. 73(6). 1360–1367. 13 indexed citations

12.

Solé, Cristina, Elsa Solà, Patrícia Huelin, et al.. (2018). Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International. 39(7). 1246–1255. 54 indexed citations

13.

Cabrera, Lourdes, et al.. (2015). Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial. Trials. 16(1). 427–427. 8 indexed citations

14.

Ramo‐Tello, Cristina, Laia Grau‐López, Mar Tintoré, et al.. (2013). A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Multiple Sclerosis Journal. 20(6). 717–725. 48 indexed citations

15.

Hoeper, Marius M., Robyn J. Barst, Robert C. Bourge, et al.. (2013). Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation. 127(10). 1128–1138. 411 indexed citations breakdown →

16.

Hoeper, Marius M., Robyn J. Barst, Nazzareno Galiè, et al.. (2011). Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). European Respiratory Journal. 38(Suppl 55). 413–413. 11 indexed citations

17.

Galiè, Nazzareno, Horst Olschewski, Ronald J. Oudiz, et al.. (2008). Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 117(23). 3010–3019. 785 indexed citations breakdown →

18.

Basagaña, María, Borja Bartolomé, Carlos Pastor‐Vargas, et al.. (2007). Allergy to human seminal fluid: Cross-reactivity with dog dander. Journal of Allergy and Clinical Immunology. 121(1). 233–239. 54 indexed citations

19.

Fontseré, Néstor, Jordi Bonal, Ferràn Torres, X Cuevas, & José Manuel Fort. (2006). [Compliance with the 2002 consensus document of the Spanish Society of Nephrology for the control of diabetic nephropathy in Catalonia (ECCODIAB)].. PubMed. 26(6). 679–87. 3 indexed citations

20.

D’Introno, Alessia, Vincenzo Solfrizzi, Anna M. Colacicco, et al.. (2005). Polymorphisms in the Oxidized Low-Density Lipoprotein Receptor-1 Gene and Risk of Alzheimer's Disease. The Journals of Gerontology Series A. 60(3). 280–284. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact